Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;40(11):2667-2673.
doi: 10.1007/s00345-022-04153-6. Epub 2022 Sep 20.

How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?

Giuseppe Fallara  1   2 , Alessandro Larcher  3   4 , Giuseppe Rosiello  3   4 , Daniele Raggi  4   5 , Laura Marandino  4   5 , Alberto Martini  6   7 , Giuseppe Basile  3   4 , Gianmarco Colandrea  3   4 , Daniele Cignoli  3   4 , Federico Belladelli  3   4 , Chiara Re  3   4 , Giacomo Musso  3   4 , Francesco Cei  3   4 , Roberto Bertini  3   4 , Alberto Briganti  3   4 , Andrea Salonia  3   4 , Francesco Montorsi  3   4 , Andrea Necchi  4   5 , Umberto Capitanio  3   4
Affiliations

How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?

Giuseppe Fallara et al. World J Urol. 2022 Nov.

Abstract

Purpose: The KEYNOTE-564 trial showed improved disease-free survival (DFS) for patients with high-risk renal cell carcinoma (RCC) receiving adjuvant pembrolizumab as compared to placebo. However, if systematically administered to all high-risk patients, it might lead to the overtreatment in a non-negligible proportion of patient. Therefore, we aimed to determine the optimal candidate for adjuvant pembrolizumab.

Methods: Within a prospectively maintained database we selected patients who fulfilled the inclusion criteria of the KEYNOTE-564. We compared baseline characteristics and oncologic outcomes in this cohort with those of the placebo arm of the KEYNOTE-564. Regression tree analyses was used to generate a risk stratification tool to predict 1-year DFS after surgery.

Results: In the off-trial setting, patients had worse tumor characteristics then in the KEYNOTE-564 placebo arm, i.e. there were more pT4 (5.4 vs. 2.7%, p = 0.046) and pN1 (15 vs. 6.3%, p < 0.001) cases. Median DFS was 29 (95% CI 21-35) months as compared to value not reached in KEYNOTE-564 and 1-year DFS was 64.2% (95% CI 59.6-69.2) as compared to 76.2% (95% CI 72.2-79.7), respectively. Patients with pN1 were at the highest risk of 1-year recurrence (1-year DFS 28.6% [95% CI 20.2-40.3]); patients without LNI, but necrosis were at intermediate risk (1-year DFS 62.5% [95% CI 56.9-68.8]); those without LNI and necrosis were at the lowest risk (1-year DFS 83.8% [95% CI 79.1-88.9]). LVI substratification furtherly improved the accuracy in the prediction of early recurrence.

Conclusions: Patients potentially eligible for adjuvant pembrolizumab have worse characteristics and DFS in the off-trial setting as compared to the placebo arm of the KEYNOTE-564. Patients with either LNI or necrosis were at the highest risk of early-recurrence, which make them the ideal candidate to adjuvant pembrolizumab.

Keywords: Adjuvant; Pembrolizumab; Progression; Recurrence; Renal cancer.

PubMed Disclaimer

Comment in

References

    1. Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H et al (2021) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. New Engl J Med 385:683–694. https://doi.org/10.1056/nejmoa2106391 - DOI - PubMed
    1. Network NCC (n.d.) Kidney Cancer Version 4.2022. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/... (accessed Decr 26, 2021).
    1. Powles T, Albiges L, Bex A, Grünwald V, Porta C, Procopio G et al (2021) ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 32:1511–1519. https://doi.org/10.1016/j.annonc.2021.09.014 - DOI - PubMed
    1. Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB et al (2021) 2021 Updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma. Eur Urol 81:134–137. https://doi.org/10.1016/j.eururo.2021.11.022 - DOI - PubMed
    1. Capitanio U, Montorsi F (2016) Renal cancer. Lancet 387:894–906. https://doi.org/10.1016/s0140-6736(15)00046-x - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources